Skip to content
PIL Logo

Abilify Maintena 300mg & 400 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe

Last Updated on eMC 12-Jul-2016 View document  | Otsuka Pharmaceuticals (UK) Ltd Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12-Jul-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 01-Apr-2016 and displayed until 12-Jul-2016

Reasons for adding or updating:

  • Change to section 3 - how to take/use

Updated on 07-Jan-2016 and displayed until 01-Apr-2016

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

Otsuka Pharmaceuticals (UK) Ltd

Company image
Address

Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ, UK

Fax

+44 (0)20 8848 0529

Telephone

+44 (0)20 3747 5300

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

aripiprazole

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue